SCHEMBL24257841

SCHEMBL24257841

N#Cc1ncc(-c2cccc(Cl)c2)c(C(F)F)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.43
DHFR P00374 1/20 0.42
NUDT1 P36639 2/20 0.41
TDO2 P48775 1/20 0.40
ADORA2A P29274 4/20 0.39
ADORA1 P30542 4/20 0.39
ALOX15 P16050 1/20 0.39
ADORA2B P29275 2/20 0.38
CYP19A1 P11511 1/20 0.37
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.35
GSR P00390 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GRM5 P41594 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453863 1.00 LRRK2 (0.43) LRRK2DHFRNUDT1TDO2ADORA2A
SCHEMBL24257707 0.80 CNR1 (0.40) ADORA2AADORA1KDM4EALDH1A1GRM5
SCHEMBL30452556 0.80 CNR1 (0.40) ADORA2AADORA1KDM4EALDH1A1GRM5
SCHEMBL30454648 0.80 DHFR (0.44) LRRK2DHFRNUDT1TDO2ADORA2A
SCHEMBL24257698 0.80 DHFR (0.44) LRRK2DHFRNUDT1TDO2ADORA2A
SCHEMBL24257691 0.76 USP7 (0.51) LRRK2DHFRNUDT1ADORA2AADORA1
SCHEMBL30452753 0.76 USP7 (0.51) LRRK2DHFRNUDT1ADORA2AADORA1
SCHEMBL24257720 0.75 FYN (0.44) LRRK2DHFRNUDT1ADORA2AADORA1
SCHEMBL30452358 0.75 FYN (0.44) LRRK2DHFRNUDT1ADORA2AADORA1
SCHEMBL24257875 0.72 KDM4E (0.44) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 LRRK2 248/4885DHFR 1618/4885NUDT1 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.